Suppr超能文献

治疗靶点 Hsp90 与癌症特征。

The therapeutic target Hsp90 and cancer hallmarks.

机构信息

Department of Cell & Developmental Biology, Graduate School of Biostudies, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan.

出版信息

Curr Pharm Des. 2013;19(3):347-65. doi: 10.2174/138161213804143725.

Abstract

Hsp90 is a major molecular chaperone that is expressed abundantly and plays a pivotal role in assisting correct folding and functionality of its client proteins in cells. The Hsp90 client proteins include a wide variety of signal transducing molecules such as protein kinases and steroid hormone receptors. Cancer is a complex disease, but most types of human cancer share common hallmarks, including self-sufficiency in growth signals, insensitivity to growth-inhibitory mechanism, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. A surprisingly large number of Hsp90-client proteins play crucial roles in establishing cancer cell hallmarks. We start the review by describing the structure and function of Hsp90 since conformational changes during the ATPase cycle of Hsp90 are closely related to its function. Many co-chaperones, including Hop, p23, Cdc37, Aha1, and PP5, work together with Hsp90 by modulating the chaperone machinery. Post-translational modifications of Hsp90 and its cochaperones are vital for their function. Many tumor-related Hsp90-client proteins, including signaling kinases, steroid hormone receptors, p53, and telomerase, are described. Hsp90 and its co-chaperones are required for the function of these tumor-promoting client proteins; therefore, inhibition of Hsp90 by specific inhibitors such as geldanamycin and its derivatives attenuates the tumor progression. Hsp90 inhibitors can be potential and effective cancer chemotherapeutic drugs with a unique profile and have been examined in clinical trials. We describe possible mechanisms why Hsp90 inhibitors show selectivity to cancer cells even though Hsp90 is essential also for normal cells. Finally, we discuss the "Hsp90-addiction" of cancer cells, and suggest a role for Hsp90 in tumor evolution.

摘要

热休克蛋白 90(Hsp90)是一种主要的分子伴侣,在细胞中大量表达,对于协助其客户蛋白的正确折叠和功能发挥着关键作用。Hsp90 的客户蛋白包括各种信号转导分子,如蛋白激酶和甾体激素受体。癌症是一种复杂的疾病,但大多数类型的人类癌症都具有共同的特征,包括生长信号的自给自足、对生长抑制机制的不敏感、逃避程序性细胞死亡、无限的复制潜力、持续的血管生成以及组织侵袭和转移。令人惊讶的是,大量的 Hsp90 客户蛋白在建立癌细胞特征方面发挥着关键作用。我们首先描述 Hsp90 的结构和功能,因为 Hsp90 的 ATP 酶循环中的构象变化与它的功能密切相关。许多共伴侣,包括 Hop、p23、Cdc37、Aha1 和 PP5,通过调节伴侣机制与 Hsp90 一起发挥作用。Hsp90 和其共伴侣的翻译后修饰对于它们的功能至关重要。许多与肿瘤相关的 Hsp90 客户蛋白,包括信号激酶、甾体激素受体、p53 和端粒酶,都有描述。Hsp90 和其共伴侣对于这些促进肿瘤的客户蛋白的功能是必需的;因此,特异性抑制剂如格尔德霉素及其衍生物抑制 Hsp90 的功能会减弱肿瘤的进展。Hsp90 抑制剂可以是具有独特特征的潜在有效的癌症化疗药物,并已在临床试验中进行了检查。我们描述了为什么 Hsp90 抑制剂对癌细胞具有选择性,即使 Hsp90 对正常细胞也是必不可少的,可能的机制。最后,我们讨论了癌细胞的“Hsp90 成瘾”,并提出了 Hsp90 在肿瘤进化中的作用。

相似文献

1
The therapeutic target Hsp90 and cancer hallmarks.
Curr Pharm Des. 2013;19(3):347-65. doi: 10.2174/138161213804143725.
2
Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Curr Pharm Des. 2005;11(9):1131-8. doi: 10.2174/1381612053507585.
3
[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. doi: 10.1254/fpj.121.33.
4
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Future Oncol. 2005 Apr;1(2):273-81. doi: 10.1517/14796694.1.2.273.
5
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Curr Med Chem. 2008;15(26):2702-17. doi: 10.2174/092986708786242895.
6
Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Curr Drug Targets. 2017;18(13):1572-1585. doi: 10.2174/1389450117666160527125522.
7
HSP90 multi-functionality in cancer.
Front Immunol. 2024 Aug 1;15:1436973. doi: 10.3389/fimmu.2024.1436973. eCollection 2024.
9
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Cancer Treat Rev. 2013 Jun;39(4):375-87. doi: 10.1016/j.ctrv.2012.10.001. Epub 2012 Nov 28.

引用本文的文献

3
Editorial: Physiological and pathological changes of the retina associated with ageing.
Front Cell Neurosci. 2025 May 8;19:1609473. doi: 10.3389/fncel.2025.1609473. eCollection 2025.
5
The Hsp90β Isoform: An Attractive Target for Drug Development.
Med Res Rev. 2025 Sep;45(5):1452-1465. doi: 10.1002/med.22114. Epub 2025 Apr 28.
6
Recent Advances in Small Molecular PET Tracers for Pancreatic Cancer Diagnosis: Preclinical Stage.
Mini Rev Med Chem. 2025;25(10):745-759. doi: 10.2174/0113895575375382250408143606.
7
Mechanism of client loading from BiP to Grp94 and its disruption by select inhibitors.
Nat Commun. 2025 Apr 15;16(1):3575. doi: 10.1038/s41467-025-58658-w.
8
Radiosynthesis and Evaluation of [F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging.
J Labelled Comp Radiopharm. 2025 Apr;68(4):e4144. doi: 10.1002/jlcr.4144.
10
A Practical Approach to Quantitatively Assessing Equilibrium-Constant Accuracy from a Single Binding Isotherm.
Precis Chem. 2024 Nov 20;3(2):89-104. doi: 10.1021/prechem.4c00085. eCollection 2025 Feb 24.

本文引用的文献

1
Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.
Mol Cell. 2012 Aug 10;47(3):434-43. doi: 10.1016/j.molcel.2012.05.015. Epub 2012 Jun 21.
2
Conformational switching of the molecular chaperone Hsp90 via regulated phosphorylation.
Mol Cell. 2012 Feb 24;45(4):517-28. doi: 10.1016/j.molcel.2011.12.031.
3
Structure of minimal tetratricopeptide repeat domain protein Tah1 reveals mechanism of its interaction with Pih1 and Hsp90.
J Biol Chem. 2012 Feb 17;287(8):5698-709. doi: 10.1074/jbc.M111.287458. Epub 2011 Dec 16.
4
Epithelial cell polarity, stem cells and cancer.
Nat Rev Cancer. 2011 Dec 15;12(1):23-38. doi: 10.1038/nrc3169.
5
Switches and latches: a biochemical tug-of-war between the kinases and phosphatases that control mitosis.
Philos Trans R Soc Lond B Biol Sci. 2011 Dec 27;366(1584):3584-94. doi: 10.1098/rstb.2011.0087.
6
The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Biochim Biophys Acta. 2012 Mar;1823(3):624-35. doi: 10.1016/j.bbamcr.2011.09.003. Epub 2011 Sep 16.
7
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.
8
Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8.
9
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53.
Nat Struct Mol Biol. 2011 Sep 4;18(10):1086-93. doi: 10.1038/nsmb.2114.
10
Post-translational modifications of Hsp90 and their contributions to chaperone regulation.
Biochim Biophys Acta. 2012 Mar;1823(3):648-55. doi: 10.1016/j.bbamcr.2011.07.018. Epub 2011 Aug 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验